Novo Nordisk’s oral version of Wegovy, a GLP-1 receptor agonist, is close to receiving FDA approval. If authorized, it would become the first weight-loss pill in its class. Currently available as an injectable, Wegovy has shown strong results in clinical trials, leading to excitement for its potential oral form. Approval would provide a new option for those seeking weight management without the need for injections. This development could improve patient adherence to treatment and make it more accessible.
Related Topics:
Why Does Bupropion Cause Weight Loss
Why Am I Not Losing Weight on Semaglutide